"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04104451","PHASE 1, OPEN-LABEL SAFETY STUDY OF UMBILICAL CORD LINING MESENCHYMAL STEM CELLS (CORLICYTE®) TO HEAL CHRONIC DIABETIC FOOT ULCERS",,"Active, not recruiting","No Results Available","Diabetic Foot Ulcer","Drug: Corlicyte","SAE|Antibodies to HLA Class I - number and percent|Antibodies to HLA Class I - Time To Development|Increase Ulcer Size|Adverse Reaction|Suspected Adverse Reaction|Suspected Serious Adverse Reaction|Change in A1c","University of Colorado, Denver","All","18 Years and older   (Adult, Older Adult)","Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-1113","November 12, 2019","September 30, 2022","September 30, 2022","September 26, 2019",,"August 12, 2022","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04104451"
